Shigella's ways of manipulating the host intestinal innate and adaptive immune system: A tool box for survival?

Immunology and Cell Biology

Volumn 85, Issue 2, 2007, Pages 119-129

  Phalipon, Armelle ^a   Sansonetti, Philippe J ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Host responses; Instestinal inflammation; Manipulation; Mucosal immunity; Shigella; Type III secretion system

Indexed keywords

CATHELICIDIN; CHEMOKINE RECEPTOR CXCR2; DEFENSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; LYMPHOTOXIN; PEPTIDOGLYCAN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOPHAGY; B LYMPHOCYTE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CELL FUNCTION; CELL INFILTRATION; CELL MEMBRANE; CYTOPLASM; CYTOSKELETON; DENDRITIC CELL; GASTROINTESTINAL TRACT; GENE EXPRESSION; HUMAN; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; INTERNALIZATION; INTESTINE EPITHELIUM CELL; MACROPHAGE; MICROORGANISM; MUCOSA INFLAMMATION; NEUTROPHIL; NONHUMAN; PHENOTYPE; REVIEW; SHIGELLA; SHIGELLOSIS; T LYMPHOCYTE; TARGET CELL;

ANIMALS; DYSENTERY, BACILLARY; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; INFLAMMATION; INTESTINES; MICROBIAL VIABILITY; MODELS, THEORETICAL; SHIGELLA; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; SHIGELLA;

EID: 33947181021     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb7100025     Document Type: Review

References (149)

1. Lindberg AA, Karnell A, Weintraub A. The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infec Dis 1991; 13: S279-S284.
2. Dupont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159: 1126-1128.
3. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull WHO 1999; 77: 651-666.
4. Van den Broek JM, Roy SK, Khan WA, Ara G, Chakraborty B, Islam S et al. Risk factors for mortality due to shigellosis: a case-control study among severely-malnourished children in Bangladesh. J Health PopulNutr 2005; 23: 259-265.
5. Khan AI, Huq S, Malek MA, Hossain MI, Talukder KA, Faruque ASG et al. Shigella serotypes among hospitalized patients in urban Bangladesh and their antimicrobial resistance. Epidemiol Infect 2004; 132: 773-777.
6. Agtini MD, Soeharno R, Lesmana M, Punjabi NH, Simanjuntak C, Wangsasaputra F et al. The burden of diarrhoea, shigellosis, and cholera in north Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis 2005; 5: 89-94.
7. Bhattacharya SKB, Bhattarai NR, Das ML. Prevalence of Shigella species and their antimicrobial resistance patterns in eastern Nepal. J Health Popul Nutr 2005; 23: 339-342.
8. Chompook P, Samosornsuk S, von Seidlein L, Jitsanguansuk S, Sirima N, Sudjai S et al. Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study. Bull WHO 2005; 83: 739-746.
9. Fulla N, Prado V, Duran C, Lagos R, Levine MM. Surveillance for antimicrobial resistance profiles among Shigella species isolated from a semirural community in the northern administrative area of Santiago, Chile. Am J Trop Med Hyg 2005; 72: 851-854.
10. Navia MM, Gascon J, Vila J. Analysis of the mechanisms of resistance to several antimicrobial agents in Shigella spp. causing travellers' diarrhoea.. Clin Microbiol Infect 2005; 11: 1044-1047.
11. Ozmert EN, Gokturk B, Yurdakok K, Yalcin SS, Gur D. Shigella antibiotic resistance in central turkey: comparison of the years 1987-1994 and 1995-2002. J Pediatr Gastroenterol Nutr 2005; 40: 359-362.
12. Pazhani GP, Ramamurthy T, Mitra U, Bhattacharya SK, Niyogi SK. Species diversity and antimicrobial resistance of Shigella spp. isolated between 2001 and 2004 from hospitalized children with diarrhoea in Kolkata (Calcutta), India. Epidemiol Infect 2005; 133: 1089-1095.
13. Zafar A, Sahir N, Bhutta ZA. Frequency of isolation of Shigella serogroups/serotypes and their antimicrobial susceptibility pattern in children from slum areas in Karachi. J Pak Med Assoc 2005; 55: 184-188.
14. Bercion R, Demartin M, Recio C, Massamba PM, Frank T, Escriba JM, Grimont F et al. Molecular epidemiology of multidrug-resistant Shigella dysenteriae type 1 causing dysentery outbreaks in Central African republic, 2003-2004. Trans Roy Soc Trop Med Hyg 2006; 100: 1151-1158.
15. Chuang YY, Huang YC, Lin SY. Outbreak of Shigella sonnei gastroenteritis in northeastern Taiwan. Pediatr Infect Dis J 2006; 25: 92-94.
16. Naheed A, Kalluri P, Talukder KA, Faruque ASG, Khatun F, Nair G et al. Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh. Lancet Infect Dis 2004; 4: 607-608.
17. Hirose K, Terajima J, Izumiya H, Tamura K, Arakawa E, Takai N et al. Antimicrobial susceptibility of Shigella sonnei isolates in Japan and molecular analysis of S. sonnei isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2005; 49: 1203-1205.
18. Talukder KA, Khajanchi B, Islam M, Islam Z, Dutta DK, Rahman M et al. Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone resistance-determining region of Shigella dysenteriae type 1. Curr Microbiol 2006; 52: 108-111.
19. Phalipon A, Sansonetti PJ. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. Crit Rev Immunol 2003; 23: 371-401.
20. Girard MP, Steele D, Chaignat CL, Kieny MP. A review of vaccine research and development: human enteric infections. Vaccine 2006; 24: 2732-2750.
21. Levine MM. Enteric infections and the vaccines to counter them: future directions. Vaccine 2006; 24: 3865-3873.
22. Mathan MM, Mathan VI. Morphology of rectal mucosa of patients with shigellosis. Rev Infect Dis 1991; 13: S314-S318.
23. Speelman P, Kabir I, Islam M. Distribution and spread of colonic lesions in shigellosis: a colonoscopic study. J Infect Dis 1984; 150: 899-903.
24. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004; 4: 953-964.
25. Van Nhieu GT, Enninga J, Sansonetti P, Grompone G. Tyrosine kinase signaling and type III effectors orchestrating Shigella invasion. Curr Opin Microbiol 2005; 8: 16-20.
26. Takeuchi AFS, Sprinz H. Experimental acute colitis in the rhesus monkey following peroral infection with Shigella flexneri. An electron microscope study. Am J Pathol 1968; 52: 503-529.
27. Rout WR, Formal SB, Giannella RA, Dammin GJ. Pathophysiology of Shigella diarrhea in rhesus-monkey: intestinal transport, morphological, and bacteriological studies. Gastroenterol 1975; 68: 270-278.
28. Etheridge ME, Hoque ATMS, Sack DA. Pathologic study of a rabbit model for shigellosis. Lab Anim Sci 1996; 46: 61-66.
29. Wassef JS, Keren DF, Mailloux JL. Role of M-cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis. Infect Immun 1989; 57: 858-863.
30. Sereny B. Experimental keratoconjunctivitis shigellosis. Acta Microbiol Acad Sci Hung 1957; 4: 367-376.
31. Formal S, Lowenthal JP, Galindo E. Experimental Shigella infection: characteristics of a fatal infection produced in guinea pigs. J Bacteriol 1958; 75: 467-470.
32. Perdomo JJ, Gounon P, Sansonetti PJ. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by Shigella flexneri. J Clin Invest 1994; 93: 633-643.
33. Perdomo OJJ, Cavaillon JM, Huerre M, Ohayon H, Gounon P, Sansonetti PJ. Acute-inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis. J Exp Med 1994; 180: 1307-1319.
34. Magalhaes JG, Philpott DJ, Nahori MA, Jehanno M, Fritz J, Le Bourhis L et al. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep 2005; 6: 1201-1207.
35. Modi WS, Yoshimura T. Isolation of novel gro genes and a phylogenetic analysis of the cxc chemokine subfamily in mammals. Mol Biol Evol 1999; 16: 180-193.
36. Girardin SE, Tournebize R, Mavris M, Page AL, Li XA, Stark GR et al. Card4/Nod1 mediates NF-kappa B and JNK activation by invasive Shigella flexneri. EMBO Rep 2001; 2: 736-742.
37. Singer M, Sansonetti PJ. IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 2004; 173: 4197-4206.
38. Voino-Yasenetsky MV, Voino-Yasenetskaya MK. Experimental pneumonia caused by bacteria of the Shigella group. Acta Morphol 1961; XI: 440-454.
39. Phalipon A, Kaufmann M, Michetti P, Cavaillon JM, Huerre M, Sansonetti PJ et al. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J Exp Med 1995; 182: 769-778.
40. Raqib R, Gustafsson A, Andersson J, Bakhiet M. A systemic downregulation of gamma interferon production is associated with acute shigellosis. Infect Immun 1997; 65: 5338-5341.
41. Fernandez MI, Thuizat A, Pedron T, Neutra M, Phalipon A, Sansonetti PJ. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microbiol 2003; 5: 481-491.
42. Martino MC, Rossi G, Martini I, Tattoli I, Chiavolini D, Phalipon A et al. Mucosal lymphoid infiltrate dominates colonic pathological changes in murine experimental shigellosis. J Infect Dis 2005; 192: 136-148.
43. Zhang Z, Jin LL, Champion G, Seydel KB, Stanley SL. Shigella infection in a SCID mouse-human intestinal xenograft model: role for neutrophils in containing bacterial dissemination in human intestine. Infect Immun 2001; 69: 3240-3247.
44. Sansonetti PJ, Kopecko DJ, Formal SB. Involvement of a plasmid in the invasive ability of Shigella flexneri. Infect Immun 1982; 35: 852-860.
45. Buchrieser C, Glaser P, Rusniok C, Nedjari H, d'Hauteville H, Kunst F et al. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Mol Microbiol 2000; 38: 760-771.
46. Mavris M, Page AL, Tournebize R, Demers B, Sansonetti P, Parsot C. Regulation of transcription by the activity of the Shigella flexneri type III secretion apparatus. Mol Microbiol 2002; 43: 1543-1553.
47. Le Gall T, Mavris M, Martino MC, Bernardini ML, Denamur E, Parsot C. Analysis of virulence plasmid gene expression defines three classes of effectors in the type III secretion system of Shigella flexneri. Microbiology 2005; 151: 951-962.
48. Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett 2005; 252: 11-18.
49. Tamano K, Aizawa S, Katayama E, Nonaka T, Imajoh-Ohmi S, Kuwae A et al. Supramolecular structure of the Shigella type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors. EMBO J 2000; 19: 3876-3887.
50. Blocker A, Jouihri N, Larquet E, Gounon P, Ebel F, Parsot C et al. Structure and composition of the Shigella flexneri 'needle complex', a part of its type III secreton. Mol Microbiol 2001; 39: 652-663.
51. Cordes FS, Komoriya K, Larquet E, Yang SX, Egelman EH, Blocker A et al. Helical structure of the needle of the type III secretion systemof Shigella flexneri. J Biol Chem 2003; 278: 17103-17107.
52. Blocker A, Gounon P, Larquet E, Niebuhr K, Cabiaux V, Parsot C et al. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 1999; 147: 683-693.
53. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol and Mol Biol Rev 1998; 62: 379-385.
54. Galan JE, Collmer A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science 1999; 284: 1322-1328.
55. Mota LJ, Cornelis GR. The bacterial injection kit: type III secretion systems. Ann Med 2005; 37: 234-249.
56. Dorman CJ, Porter ME. The Shigella virulence gene regulatory cascade: a paradigm of bacterial gene control mechanisms. Mol Microbiol 1998; 29: 677-684.
57. Bernardini ML, Mounier J, Dhauteville H, Coquisrondon M, Sansonetti PJ. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intracellular and intercellular spread through interaction with F-actin. Proc Natl Acad Sci 1989; 86: 3867-3871.
58. Lett MC, Sasakawa C, Okada N, Sakai T, Makino S, Yamada M et al. VirG, a plasmid-coded virulence gene of Shigella flexneri: identification of the VirG protein and determination of the complete coding sequence. J Bacteriol 1989; 171: 353-359.
59. Goldberg MB, Barzu O, Parsot C, Sansonetti PJ. Unipolar localization and ATPase activity of IcsA, a Shigella flexneri protein involved in intracellular movement. J Bacteriol 1993; 175: 2189-2196.
60. Egile C, dHauteville H, Parsot C, Sansonetti PJ. SopA, the outer membrane protease responsible for polar localization of IcsA in Shigella flexneri. Mol Microbiol 1997; 23: 1063-1073.
61. Shere KD, Sallustio S, Manessis A, DAversa TG, Goldberg MB. Disruption of IcsP, the major Shigella protease that cleaves IcsA, accelerates actin-based motility. Mol Microbiol 1997; 25: 451-462.
62. Nakata N, Sasakawa C, Okada N, Tobe T, Fukuda I, Suzuki T et al. Identification and characterization of virK, a virulence-associated large plasmid gene essential for intercellular spreading of Shigella flexneri. Mol Microbiol 1992; 6: 2387-2395.
63. d'Hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J et al. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002; 168: 5240-5251.
64. Benjelloun-Touimi Z, Tahar MS, Montecucco C, Sansonetti PJ, Parsot C. SepA, the 110 kDa protein secreted by Shigella flexneri: two-domain structure and proteolytic activity. Microbiology 1998; 144: 1815-1822.
65. Gorden J, Small PLC. Acid resistance in enteric bacteria. Infect Immun 1993; 61: 364-367.
66. Hancock REW, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci 2000; 97: 8856-8861.
67. Ganz T. Immunology: defensins and host defense. Science 1999; 286: 420-421.
68. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leuk Biol 2004; 75: 39-48.
69. Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 2001; 7: 180-185.
70. Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci 2006; 103: 9178-9183.
71. Gomez HF, Herrera-Insua I, Siddiqui MM, Diaz-Gonzalez VA, Caceres E, Newburg DS et al. Protective role of human lactoferrin against invasion of Shigella flexneri M90T. Bioactive Components Hum Milk 2001; 501: 457-467.
72. Raqib R, Wretlind B, Andersson J, Lindberg AA. Cytokine secretion in acute shigellosis is correlated to disease-activity and directed more to stool than to plasma. J Infect Dis 1995; 171: 376-384.
73. Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature 1992; 358: 167-169.
74. Zychlinsky A, Fitting C, Cavaillon JM, Sansonetti PJ. Interleukin-1 is released by murine macrophages during apoptosis induced by Shigella flexneri. J Clin Invest 1994; 94: 1328-1332.
75. Edgeworth JD, Spencer J, Phalipon A, Griffin GE, Sansonetti PJ. Cytotoxicity and interleukin-1 beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells. Eur J Immunol 2002; 32: 1464-1471.
76. Zychlinsky A, Thirumalai K, Arondel J, Cantey JR, Aliprantis AO, Sansonetti PJ. In vivo apoptosis in Shigella flexneri infections. Infect Immun 1996; 64: 5357-5365.
77. Raqib R, Ekberg C, Sharkar P, Bardhan PK, Zychlinsky A, Sansonetti PJ et al. Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2. Infect Immun 2002; 70: 3199-3207.
78. Hilbi H, Puro RJ, Zychlinsky A. Tripeptidyl peptidase II promotes maturation of caspase-1 in Shigella flexneri-induced macrophage apoptosis. Infect Immun 2000; 68: 5502-5508.
79. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S et al. Caspase-1 activation of IL-1 beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 2000; 12: 581-590.
80. Sansonetti PJ, Arondel J, Cavaillon JM, Huerre M. Role of interleukin-1 in the pathogenesis of experimental shigellosis. J Clin Invest 1995; 96: 884-892.
81. Arondel J, Singer M, Matsukawa A, Zychlinsky A, Sansonetti PJ. Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental shigellosis. Infect Immun 1999; 67: 6056-6066.
82. Pelkonen SPG. Recombinant interleukin-1 stimulates clearance of Escherichia coli K1 bacteraemia. Microbiol Pathogenesis 1989; 6: 415-424.
83. Van der Meer JW, Vogels M, Curfs JH, Eling WM. Interleukin-1 as a possible agent for treatment of infection. Eur J Clin Microbiol Infect Dis 1993; 12: S73-S77.
84. Ogura YSF, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell Microbiol 2006; 25: 659-662.
85. Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006; 440: 233-236.
86. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP et al. Critical role for Nalp3/cias1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24: 317-327.
87. Kirkegaard K, Taylor MP, Jackson WT. Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol 2004; 2: 301-314.
88. Amer AO, Swanson MS. Autophagy is an immediate macrophage response to Legionella pneumophila. Cell Microbiol 2005; 7: 765-778.
89. Gutierrez MG, Vazquez CL, Munafo DB, Zoppino FC, Beron W, Rabinovitch M, Colombo MI. Autophagy induction favours the generation and maturation of the Coxiella-replicative vacuoles. Cell Microbiol 2005; 7: 981-993.
90. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C. Escape of intracellular Shigella from autophagy. Science 2005; 307: 727-731.
91. Pedron T, Thibault C, Sansonetti PJ. The invasive phenotype of Shigella flexneri directs a distinct gene expression pattern in the human intestinal epithelial cell line Caco-2. J Biol Chem 2003; 278: 33878-33886.
92. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
93. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Ann Rev Immunol 2000; 18: 621-627.
94. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002; 3: 20-26.
95. Okamura N, Nakaya R, Suzuki K, Kondo S, Hisatsune K, Imagawa Y et al. Differences among Shigella spp in susceptibility to the bactericidal activity of human serum. J Gen Microbiol 1988; 134: 2057-2065.
96. West NP, Sansonetti P, Mounier J, Exley RM, Parsot C, Guadagnini S, Prevost MC et al. Optimization of virulence functions through glucosylation of Shigella LPS. Science 2005; 307: 1313-1317.
97. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001; 167: 1609-1616.
98. Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, Kagnoff MF. NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacterial. J Immunol 1999; 163: 1457-1466.
99. Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ. Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 2000; 165: 903-914.
100. Wenneras C, Ave P, Huerre M, Arondel J, Ulevitch RJ, Mathison JC et al. Blockade of CD14 increases Shigella-mediated invasion and tissue destruction. J Immunol 2000; 164: 3214-3221.
101. Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004; 41: 1099-1108.
102. Viala J, Chaput C, Boneca IG, Girardin SE, Moran AP, Huerre MR et al. Nod1-dependent proinflammatory responses to Helicobacter pylori infection in gastric epithelial cells. Gastroenterology 2003; 124: A43.
103. Girardin SE, Boneca IG, Carneiro LAM, Antignac A, Jehanno M, Viala J et al. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 2003; 300: 1584-1587.
104. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278: 8869-8872.
105. Russell RK, Nimmo ER, Satsangi J. Molecular genetics of crohn's disease. Curr Opin Gen Dev 2004; 14: 264-270.
106. Sansonetti PJ, Arondel J, Huerre M, Harada A, Matsushima K. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. Infect Immun 1999; 67: 1471-1480.
107. Beatty WL, Sansonetti PJ. Role of lipopolysaccharide in signaling to subepithelial polymorphonuclear leukocytes. Infect Immun 1997; 65: 4395-4404.
108. Sansonetti PJ, Arondel J. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 1989; 7: 443-450.
109. Ingersoll MA, Moss JE, Weinrauch Y, Fisher PE, Groisman EA, Zychlinsky A. The ShiA protein encoded by the Shigella flexneri Shi-2 pathogenicity island attenuates inflammation. Cell Microbiol 2003; 5: 797-807.
110. Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ, Parsot C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci 2005; 102: 14046-14051.
111. Viboud GI, Bliska JB. Yersinia outer proteins: Role in modulation of host cell signaling responses and pathogenesis. Ann Rev Microbiol 2005; 59: 69-89.
112. Shtrichman R, Samuel CE. The role of gamma interferon in antimicrobial immunity. Cur Opin Microbiol 2001; 4: 251-259.
113. Niesel DW, Hess CB, Cho YJ, Klimpel KD, Klimpel GR. Natural and recombinant interferons inhibit epithelial-cell invasion by Shigella spp. Infect Immun 1986; 52: 828-833.
114. Way SS, Borczuk AC, Dominitz R, Goldberg MB. An essential role for gamma interferon in innate resistance to Shigella flexneri infection. Infect Immun 1998; 66: 1342-1348.
115. Islam MM, Azad AK, Bardhan PK, Raqib R, Islam D. Pathology of shigellosis and its complications. Histopathology 1994; 24: 65-71.
116. Islam D, Wretlind B, Lindberg AA, Christensson B. Changes in the peripheral blood T-cell receptor V beta repertoire in vivo and in vitro during shigellosis. Infect Immun 1996; 64: 1391-1399.
117. Islam D, Christensson B. Disease-dependent changes in T-cell populations in patients with shigellosis. Apmis 2000; 108: 251-260.
118. Le Barillec K, Magalhaes J, Corcuff E, Thuizat A, Sansonetti PJ, Phalipon A, Di Santo JP. Roles for T and NK cells in the innate immune response to Shigella flexneri. J Immunol 2005; 175: 1735-1740.
119. Raqib R, Lindberg AA, Bjork L, Bardhan PK, Wretlind B, Andersson U et al. Down-regulation of gamma-interferon, tumor-necrosis-factor type-I, interleukin-1 (IL-1) type-1, IL-3, IL-4, and transforming growth-factor-beta type-I receptors at the local site during the acute-phase of Shigella infection. Infect Immun 1995; 63: 3079-3087.
120. Raqib R, Ljungdahl A, Lindberg AA, Andersson U, Andersson J. Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection. Gut 1996; 38: 328-336.
121. Lowell GH, Macdermott RP, Summers PL, Reeder AA, Bertovich MJ, Formal SB. Antibody-dependent cell-mediated anti-bacterial activity: K lymphocytes, monocytes, and granulocytes are effective against Shigella. J Immunol 1980; 125: 2778-2784.
122. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A. Neutrophil elastase targets virulence factors of enterobacteria. Nature 2002; 417: 91-94.
123. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
124. Urban CF, Lourido S, Zychlinsky A. How do microbes evade neutrophil killing? Cell Microbiol 2006; 8: 1687-1696.
125. McCaffrey RL, Allen LA. Pivotal advance: Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. J Leukoc Biol 2006; 80: 1224-1230.
126. Beiter KWF, Albiger B, Normark S, Zychlinsky A, Henriques-Normark B. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol 2006; 16: 401-407.
127. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 2006; 16: 396-400.
128. Francois M, Le Cabec V, Dupont MA, Sansonetti PJ, Maridonneau-Parini I. Induction of necrosis in human neutrophils by Shigella flexneri requires type III secretion, IpaB and IpaC invasins, and actin polymerization. Infect Immun 2000; 68: 1289-1296.
129. Raqib R, Reinholt FP, Bardhan PK, Karnell A, Lindberg AA. Immunopathological patterns in the rectal mucosa of patients with shigellosis: expression of HLA-DR antigens and T-lymphocyte subsets. APMIS 1994; 102: 371-380.
130. Islam D, Veress B, Bardhan PK, Lindberg AA, Christensson B. In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis. Infect Immun 1997; 65: 739-749.
131. Way SS, Borczuk AC, Goldberg MB. Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A. Infect Immun 1999; 67: 2001-2004.
132. Phalipon A, Costachel C, Grandjean C, Thuizat A, Guerreiro C, Tanguy M et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J Immunol 2006; 176: 1686-1694.
133. Raqib R, Mia SMS, Qadri F, Alam TI, Alam NH, Chowdhury AK et al. Innate immune responses in children and adults with shigellosis. Infect Immun 2000; 68: 3620-3629.
134. Raqib R, Qadri F, Sarker P, Mia SMS, Sansonnetti PJ, Albert MJ et al. Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults. Scand J Immunol 2002; 55: 414-423.
135. Fearon DT, Locksley RM. Elements of immunity: the instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50-54.
136. Janeway CA, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998; 10: 349-350.
137. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947-950.
138. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002; 14: 129-135.
139. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
140. Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, Andersson J. Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun 1995; 63: 289-296.
141. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006; 117: 433-442.
142. Bellone M. Apoptosis, cross-presentation, and the fate of the antigen specific immune response. Apoptosis 2000; 5: 307-314.
143. Gerondakis SGR, Rourke I, Grossmann M. The regulation and roles of Rel/NF-kappaB transcription factors during lymphocyte activation. Curr Opin Immunol 1998; 3: 353-359.
144. Banchereau JSR. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
145. Kojima HAY, Yanai Y, Nagaoka K, Takeuchi M, Ohta T, Ikegami H et al. An essential role for NF-kappaB in IL-18-induced IFN-gamma expression in KG-1 cells. J Immunol 1999; 162: 5063-5069.
146. Baldari CT, Tonello F, Paccani SR, Montecucco C. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol 2006; 9: 434-440.
147. Galan JE. Bacterial toxins and the immune system: show me the in vivo targets. J Exp Med 2005; 7: 321-323.
148. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. Plague bacteria target immune cells during infection. Science 2005; 309: 1739-1741.
149. Hornef MW, Wick MJ, Rhen M, Normark S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 2002; 3: 1033-1040.